Glioblastoma Multiforme Market
Glioblastoma Multiforme Market Size, Share & Industry Analysis, By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy), By Drug Class (Temozolomide, Bevacizumab, Carmustine Wafers, Others), By End User (Hospitals, Speciality Clinics, Cancer and Radiation Therapy Centres), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa): Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
“The global glioblastoma multiforme market is expected to increase at an 8.5% CAGR from 2024 to 2031. The market size is estimated to reach XX in 2024 and YY in 2031.”
North America dominates the market, accounting for around YY% of total worldwide market share. Key metrics include the rising prevalence of glioblastoma multiforme, advances in diagnostic and treatment technology, and increased investment in R&D for novel medicines.
The glioblastoma multiforme market is steadily expanding, owing to the increasing occurrence of brain tumours, an ageing population, and a pressing demand for more effective treatment choices. The complicated nature of glioblastoma, as well as its dismal prognosis, continue to drive substantial research and clinical trials, which could lead to novel therapeutic methods.
Glioblastoma Multiforme Market Dynamics:
Market Trend: Emergence of Personalised Medicine and Targeted Therapies
The glioblastoma multiforme market is rapidly shifting towards personalised medicine and targeted therapeutics. Advances in molecular diagnostics and a better understanding of individual tumour genetics are driving this trend. Precision medicine techniques seek to customise therapies to specific genetic mutations or biomarkers, potentially increasing efficacy while lowering negative effects.
Recent clinical trials have yielded encouraging findings for targeted treatments in glioblastoma. Phase II research of 180 patients found that a tailored therapeutic approach based on tumour molecular profiling increased progression-free survival by 35% compared to usual treatment. According to our research analysis, by 2026, more than 40% of glioblastoma patients may receive targeted therapy as part of their treatment regimen, possibly altering the management of this aggressive illness.
Market Driver: Increasing Incidence of Glioblastoma and Ageing Population
The increased incidence of glioblastoma multiforme, particularly in older populations, is a major driver of market expansion. Glioblastoma is the most common and dangerous type of malignant brain tumor in adults, and its incidence rates rise with age.
According to the American Association of Neurological Surgeons, the incidence of glioblastoma is around 3.19 per 100,000 people, with greater rates in developed countries. The American Cancer Society predicts that around 24,530 malignant tumors of the brain or spinal cord will be diagnosed in the United States in 2021, with glioblastoma accounting for a sizable proportion. The aging global population, notably in North America and Europe, is predicted to increase the prevalence of glioblastoma.
According to our research analysis, the incidence of glioblastoma cases among those over the age of 65 is expected to climb by 20% by 2030, resulting in a larger patient population in need of innovative treatments.
Market restraint: high treatment costs and limited efficacy of current therapies
While the glioblastoma multiforme market is growing, it confronts substantial obstacles due to the high cost of treatment and the poor efficacy of current therapies. Despite intense and costly treatment regimens, glioblastoma has a dismal survival rate due to its aggressive nature and resistance to standard treatments.
A cost analysis research found that the average overall cost of care for a glioblastoma patient in the United States can approach $200,000 in the first year of diagnosis, including significant out-of-pocket payments for patients and families. The exorbitant expense of new medicines, such as tumour-treating fields (TTFields) devices, which can cost up to $20,000 per month, creates major barriers to access for many patients.
Furthermore, the low efficacy of current standard-of-care medications, with median survival rates of about 12–15 months even with optimum therapy, highlights the critical need for more effective and economical treatment choices. These concerns have the potential to restrict market growth and reduce patient access to cutting-edge medicines, particularly in places with limited healthcare resources.
Segment Overview:
The chemotherapy segment dominates the glioblastoma multiforme market, accounting for over YY% of the market share.
Chemotherapy, notably with the medication temozolomide, is still the cornerstone of glioblastoma treatment due to its proven success in conjunction with surgery and radiation therapy. This segment's dominance stems from the extensive usage of temozolomide as the first-line treatment for newly diagnosed glioblastoma patients.
As per our data demonstrates the chemotherapy segment's strength. A survey of 300 neuro-oncologists found that 90% of them use temozolomide-based chemotherapy as part of the initial treatment plan for glioblastoma patients. The market is likely to maintain its lead, with a 7.5% CAGR through 2031, owing to ongoing research into optimizing chemotherapy regimens and discovering innovative chemotherapeutic drugs.
The immunotherapy segment has the fastest-growing market share, owing to promising clinical trial outcomes and the prospect of long-term survival advantages. According to research data statistics, the number of immunotherapy clinical trials for glioblastoma has increased by 50%. over the previous three years, with checkpoint inhibitors and CAR-T cell treatments showing particularly promising results in early-phase studies.
Regional Outlook:
North America leads the global glioblastoma multiforme market, with a market share of approximately YY%.
North America's dominance in the glioblastoma multiforme market is due to improved healthcare infrastructure, high healthcare expenditure, and the presence of significant market participants and research institutions. The United States in particular has led glioblastoma research and clinical trials.
Glioblastoma affects roughly 14,000 people in the United States each year, according to the National Brain Tumor Society. The region's strong emphasis on cancer research and development is reflected in the substantial funds dedicated to brain tumor investigations. For example, the National Cancer Institute (NCI) allocated more than $200 million to brain and central nervous system cancer research in 2020 alone. This dynamic research environment, combined with favorable reimbursement regulations for cancer treatments, is driving market expansion in the region.
Europe follows closely after North America, accounting for approximately YY% of the market share. The region's market places a major emphasis on collaborative research activities and the development of novel medicines. The European Union's Horizon Europe initiative has provided significant money for cancer research, including brain tumors, thus promoting advances in glioblastoma treatment. Countries such as Germany, the United Kingdom, and France are pioneers in the adoption of innovative medicines and large-scale clinical studies for glioblastoma.
The Asia-Pacific region is emerging as a rapidly increasing market for glioblastoma multiforme treatments, with a projected CAGR of 10.5% by 2031. Countries such as China, Japan, and India are generating tremendous growth as they improve healthcare infrastructure, increase healthcare spending, and raise awareness of sophisticated cancer treatments. For example, China's National Cancer Centre reported a considerable increase in brain tumor diagnoses, with glioblastoma accounting for a sizable share, underscoring the growing need for effective therapies in the region.
Competitive Intelligence:
The glioblastoma multiforme market is characterized by fierce competition between pharmaceutical and biotechnology companies seeking to create more effective treatments for this difficult malignancy. To strengthen their market positions, key firms are investing in novel medication research, strategic collaborations, and increasing their clinical trial pipelines.
Leading market players, such as Merck & Co., Inc. and Bristol-Myers Squibb Company, have developed strong positions through their oncology portfolios and ongoing research in glioblastoma. Merck's Temodar (temozolomide) remains a cornerstone of glioblastoma treatment, and the company continues to invest in other techniques, such as immunotherapy combos.
Emerging players are making great progress in developing targeted and immunotherapy-based therapies for glioblastoma. For example, Novocure Ltd. has shown success with its Tumour Treating Fields (TTFields) technology, with a 15% year-over-year rise in active patients utilising the Optune device for glioblastoma therapy in 2023. The company's emphasis on non-invasive treatment options has resonated well with patients and healthcare providers looking for alternatives to established therapy.
The market has also seen an increase in joint efforts and license agreements. In 2023, over 25 key partnerships and licensing arrangements were announced in the glioblastoma arena, with the goal of integrating knowledge in areas such as immunotherapy, targeted medicines, and drug delivery technology to produce more effective treatment techniques.
Analyst Opinion:
The Glioblastoma Multiforme Market is expected to have substantial growth and possible breakthroughs in the coming years, owing to the urgent need for more effective treatments and quick development in understanding the molecular underpinnings of this aggressive malignancy. We predict that the combination of precision medicine approaches, such as genetic profiling and targeted treatments, will become increasingly significant in glioblastoma treatment, potentially leading to better patient outcomes and survival rates.
The advent of immunotherapy as a promising treatment option for glioblastoma opens up new opportunities for innovation. While current immunotherapy techniques have demonstrated limited efficacy as monotherapies, ongoing research into combination strategies and innovative immune-based treatments may open up new avenues for long-term illness management.
Furthermore, we anticipate a rising emphasis on creating medicines that can successfully penetrate the blood-brain barrier and sustain therapeutic concentrations in the tumour microenvironment. Advances in drug delivery technologies, including nanoparticle-based systems and convection-enhanced distribution, have the potential to greatly improve the efficacy of current and future glioblastoma treatments.
Major Players:
-
Merck & Co., Inc.
-
Bristol-Myers Squibb Company
-
F. Hoffmann-La Roche Ltd
-
Novocure Ltd.
-
Amgen Inc.
-
Pfizer Inc.
-
Novartis AG
-
AbbVie Inc.
-
Genentech, Inc. (a member of the Roche Group)
-
Celldex Therapeutics, Inc.
Key Developments:
-
In September 2023, Bristol-Myers Squibb revealed excellent findings from a phase II trial combining its immunotherapy medications nivolumab and ipilimumab with radiation therapy in newly diagnosed glioblastoma patients, demonstrating a 25% improvement in progression-free survival over standard treatment.
-
Novocure Ltd. got FDA approval in April 2024 for an updated version of its Optune device with increased portability and user interface, with the goal of boosting patient compliance and quality of life for glioblastoma patients undergoing TTFields therapy.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium)
5. COMPANY PROFILES
5.1. Merck & Co., Inc.
5.2. Bristol-Myers Squibb Company
5.3. F. Hoffmann-La Roche Ltd
5.4. Novocure Ltd.
5.5. Amgen Inc.
5.6. Pfizer Inc.
5.7. Novartis AG
5.8. AbbVie Inc.
5.9. Genentech, Inc. (a member of the Roche Group)
5.10. Celldex Therapeutics, Inc. (LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Emergence of Personalised Medicine and Targeted Therapies
6.1.2. Advancements in immunotherapy approaches for glioblastoma
6.1.3. Integration of AI and machine learning in drug discovery and treatment planning
6.2. Market Drivers
6.2.1. Increasing Incidence of Glioblastoma and Ageing Population
6.2.2. Growing investments in research and development for novel therapies
6.2.3. Improving diagnostic technologies for early detection
6.3. Market Restraints
6.3.1. High treatment costs and limited efficacy of current therapies
6.3.2. Challenges in drug delivery across the blood-brain barrier
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY TREATMENT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Surgery
7.1.1. Craniotomy
7.1.2. Minimally invasive procedures
7.2. Radiation Therapy
7.2.1. External beam radiation therapy
7.2.2. Brachytherapy
7.3. Chemotherapy
7.3.1. Temozolomide-based regimens
7.3.2. Other chemotherapy agents
7.4. Targeted Therapy
7.4.1. Small-molecule inhibitors
7.4.2. Monoclonal antibodies
7.5. Immunotherapy
7.5.1. Checkpoint inhibitors
7.5.2. CAR-T cell therapies
8. BY DRUG CLASS (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH)--2020-2031)
8.1. Temozolomide
8.1.1. Brand name products
8.1.2. Generic formulations
8.2. Bevacizumab
8.2.1. First-line treatment
8.2.2. Recurrent glioblastoma
8.3. Carmustine Wafers
8.3.1. Newly diagnosed glioblastoma
8.3.2. Recurrent glioblastoma
8.4. Others
8.4.1. Emerging drug candidates
8.4.2. Combination therapies
9. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospitals
9.1.1. Academic medical centres
9.1.2. Community hospitals
9.2. Speciality Clinics
9.2.1. Neuro-oncology clinics
9.2.2. Multidisciplinary cancer centres
9.3. Cancer and Radiation Therapy Centres
9.3.1. Freestanding radiation therapy centres
9.3.2. Hospital-affiliated cancer centres
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (2020-2031)
By Treatment Type:
-
Surgery
-
Radiation Therapy
-
Chemotherapy
-
Targeted Therapy
-
Immunotherapy
By Drug Class:
-
Temozolomide
-
Bevacizumab
-
Carmustine Wafers
-
Others
By End User:
-
Hospitals
-
Speciality Clinics
-
Cancer and radiation therapy centres
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511